Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 4
1982 5
1983 11
1984 12
1985 18
1986 16
1987 37
1988 38
1989 40
1990 54
1991 45
1992 65
1993 54
1994 59
1995 70
1996 50
1997 63
1998 72
1999 99
2000 93
2001 76
2002 70
2003 89
2004 85
2005 104
2006 106
2007 113
2008 114
2009 133
2010 145
2011 150
2012 148
2013 149
2014 152
2015 134
2016 158
2017 130
2018 121
2019 132
2020 37
Text availability
Article attribute
Article type
Publication date

Search Results

3,025 results
Results by year
Filters applied: . Clear all
Page 1
Inflammatory bowel disease and the elderly: a review.
Taleban S, Colombel JF, Mohler MJ, Fain MJ. Taleban S, et al. J Crohns Colitis. 2015 Jun;9(6):507-15. doi: 10.1093/ecco-jcc/jjv059. Epub 2015 Apr 13. J Crohns Colitis. 2015. PMID: 25870198 Review.
Inflammatory bowel disease among the elderly is common, with growing incident and prevalence rates. Compared with younger IBD patients, genetics contribute less to the pathogenesis of older-onset IBD, with dysbiosis and dysregulation of the immune system play
Inflammatory bowel disease among the elderly is common, with growing incident and prevalence rates. Compared with young
Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R, Kin C, Park KT. Yu H, et al. Aliment Pharmacol Ther. 2018 Feb;47(3):364-370. doi: 10.1111/apt.14430. Epub 2017 Nov 22. Aliment Pharmacol Ther. 2018. PMID: 29164650 Free PMC article.
BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. ...METHODS: The Truven MarketScan(®) Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis ( …
BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) ar …
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. Doherty G, et al. J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101. J Crohns Colitis. 2018. PMID: 28981623 Free article. Review.
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and Crohn's Disease [CD]. For each major class of IBD medications [5-aminosalicyclates, immunomodulators, and biologic agents], used alone or in combination, there is …
Clinically effective therapies now exist for remission maintenance in both ulcerative colitis [UC] and Crohn's Disease [CD]. For each …
Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease.
Fan H, Du J, Liu X, Zheng WW, Zhuang ZH, Wang CD, Gao R. Fan H, et al. Turk J Gastroenterol. 2019 Aug;30(8):680-685. doi: 10.5152/tjg.2019.18426. Turk J Gastroenterol. 2019. PMID: 31418411 Free PMC article. Clinical Trial.
BACKGROUND/AIMS: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probiotics on the microflora composition and prognosis in patients with inflammatory bowel disease (IBD). ...CONCLUSION: The combination o …
BACKGROUND/AIMS: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probiotics on the m …
Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, Cole AT, Cooper SC, Creed T, Cummings F, de Boer NK, D'Inca R, D'Souza R, Daneshmend TK, Delaney M, Dhar A, Direkze N, Dunckley P, Gaya DR, Gearry R, Gore S, Halfvarson J, Hart A, Hawkey CJ, Hoentjen F, Iqbal T, Irving P, Lal S, Lawrance I, Lees CW, Lockett M, Mann S, Mansfield J, Mowat C, Mulgrew CJ, Muller F, Murray C, Oram R, Orchard T, Parkes M, Phillips R, Pollok R, Radford-Smith G, Sebastian S, Sen S, Shirazi T, Silverberg M, Solomon L, Sturniolo GC, Thomas M, Tremelling M, Tsianos EV, Watts D, Weaver S, Weersma RK, Wesley E, Holden A, Ahmad T. Heap GA, et al. J Crohns Colitis. 2016 Feb;10(2):149-58. doi: 10.1093/ecco-jcc/jjv219. Epub 2015 Nov 29. J Crohns Colitis. 2016. PMID: 26619893 Clinical Trial.
METHODS: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion criteria included normal renal function prior to commencing 5-ASA, ≥50% rise in creatinine any time after starting 5-ASA, and physician opinion …
METHODS: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion criteria included …
Towards improved control of inflammatory bowel disease.
Eberhardson M, Hedin CRH, Carlson M, Tarnawski L, Levine YA, Olofsson PS. Eberhardson M, et al. Scand J Immunol. 2019 Mar;89(3):e12745. doi: 10.1111/sji.12745. Scand J Immunol. 2019. PMID: 30582196 Free article. Review.
Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in genetically susceptible individuals, resulting in chronic intestinal inflammation. ...The mainstay of modern IBD treatment is suppression of the i
Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in geneti
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X, Ma J, Wang K, Zhang H. Qiu X, et al. Oncotarget. 2017 Jan 3;8(1):1031-1045. doi: 10.18632/oncotarget.13715. Oncotarget. 2017. PMID: 27906680 Free PMC article. Review.
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) has been widely studied; however, the results remain conflicting. The aim of this study was to systematically revi …
BACKGROUND AND AIMS: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel
Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
Sedano Muñoz R, Quera Pino R, Ibáñez Lazo P, Figueroa Corona C, Flores Pérez L. Sedano Muñoz R, et al. Gastroenterol Hepatol. 2019 May;42(5):339-347. doi: 10.1016/j.gastrohep.2019.01.013. Epub 2019 Apr 4. Gastroenterol Hepatol. 2019. PMID: 30954317 Review. English, Spanish.
The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are to achieve clinical, endoscopic and ideally histological remission and improve the quality of life of these patients. ...This review aims to …
The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are t …
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Derwa Y, et al. Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203. Epub 2017 Jun 27. Aliment Pharmacol Ther. 2017. PMID: 28653751 Free article. Review.
BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis. ...Eligible randomised controlled trials (RCTs) recruited adu …
BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence imp …
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
Spagnuolo R, Cosco C, Mancina RM, Ruggiero G, Garieri P, Cosco V, Doldo P. Spagnuolo R, et al. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):102-107. Eur Rev Med Pharmacol Sci. 2017. PMID: 28724171 Free article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy of a mixture of beta-glucan, inositol and digestive enzymes in improving gastrointestinal symptoms in patients affected by inflammatory bowel disease (IBD)-irritable bowel syndrome (IBS). ...Patients who underwent on …
OBJECTIVE: To evaluate the efficacy of a mixture of beta-glucan, inositol and digestive enzymes in improving gastrointestinal symptoms in pa …
3,025 results
Jump to page
Feedback